About
Harr received his M.D. from the Johns Hopkins University School of Medicine and a B.A. in economics from the College of the Holy Cross, and he was a resident in internal medicine at the University of California, San Francisco. He worked at Morgan Stanley as a biotechnology research analyst and then as head of biotechnology investment banking. He was Chief Financial Officer and Head of Corporate Development at Juno from April 2014 until its acquisition by Celgene in March 2018. Whoo also has pages for other biotechnology leaders, including Emil Kakkis of Ultragenyx and Helmy Eltoukhy of Guardant Health.
Whoo compiled this page from public sources: Sana Biotechnology proxy statement 2026, Sana Biotechnology Form 10-Q, September 2026, Sana Biotechnology Q3 2026 results release. It is not affiliated with or endorsed by Steven Harr. Are you Steven Harr? Claim this page, or write to [email protected] to correct or remove it. Last updated: 2026-11-18.
Want a page like this? Create yours from your résumé.
Experience
Co-founder, President and Chief Executive Officer — Sana Biotechnology
September 2018 – Present | Seattle, Washington
- Board member since October 2018
- Responsible for overall financial and operational strategy until Celgene acquired the company
- Earlier at Morgan Stanley, Lead Biotech Research Analyst and Co-head of Global Healthcare Research
Chief Financial Officer and Head of Corporate Development — Juno
April 2014 – March 2018